secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2023-09-21T23:59:59+00:00
Accession:  0001689375-23-000068
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada doses first participant in Phase 1 trial of ENTR-601-44 for Duchenne MD
-------------------------------------------------------------------------------

- First participant dosed in Phase 1 trial of ENTR-601-44 for DMD patients amenable to exon 44 skipping.
- Trial conducted in UK; targets ~40 healthy male volunteers; endpoints include safety, PK, and target engagement.
- Data from the Phase 1 trial expected in the second half of 2024.
- Initiation marks Entrada's transition into a clinical-stage company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000068/0001689375-23-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000068/trda-20230921.htm
  HTML page:      https://secwatch.observer/filing/0001689375-23-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer